These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35647563)

  • 1. Accounting for population structure in genetic studies of cystic fibrosis.
    Kingston H; Stilp AM; Gordon W; Broome J; Gogarten SM; Ling H; Barnard J; Dugan-Perez S; Ellinor PT; Gabriel S; Germer S; Gibbs RA; Gupta N; Rice K; Smith AV; Zody MC; ; ; Blackman SM; Cutting G; Knowles MR; Zhou YH; Rosenfeld M; Gibson RL; Bamshad M; Fohner A; Blue EE
    HGG Adv; 2022 Jul; 3(3):100117. PubMed ID: 35647563
    [No Abstract]   [Full Text] [Related]  

  • 2. High frequency of complex CFTR alleles associated with c.1521_1523delCTT (F508del) in Russian cystic fibrosis patients.
    Petrova NV; Kashirskaya NY; Vasilyeva TA; Balinova NV; Marakhonov AV; Kondratyeva EI; Zhekaite EK; Voronkova AY; Kutsev SI; Zinchenko RA
    BMC Genomics; 2022 Apr; 23(1):252. PubMed ID: 35365085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic Variants and Genotypes of the
    Chernykh V; Krasovsky S; Solovova O; Adyan T; Stepanova A; Marnat E; Shtaut M; Sedova A; Sorokina T; Beskorovainaya T; Kondratyeva E; Shchagina O; Polyakov A
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tensin 1 (TNS1) is a modifier gene for low body mass index (BMI) in homozygous [F508del]CFTR patients.
    Walton NI; Zhang X; Soltis AR; Starr J; Dalgard CL; Wilkerson MD; Conrad D; Pollard HB
    Physiol Rep; 2021 Jun; 9(11):e14886. PubMed ID: 34086412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep resequencing of
    Vecchio-Pagán B; Blackman SM; Lee M; Atalar M; Pellicore MJ; Pace RG; Franca AL; Raraigh KS; Sharma N; Knowles MR; Cutting GR
    Hum Genome Var; 2016; 3():16038. PubMed ID: 27917292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L138ins Variant of the
    Chernykh V; Sorokina T; Sedova A; Shtaut M; Solovova O; Marnat E; Adyan T; Beskorovaynaya T; Stepanova A; Shchagina O; Polyakov A
    Genes (Basel); 2023 Jul; 14(7):. PubMed ID: 37510311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of IVS6A GATT polymorphism of CFTR gene with cystic fibrosis: first study in CF and normal Tunisian population.
    Chaima S; Sondess HF; Khedija B; Ahmed M; Taieb M
    Ann Biol Clin (Paris); 2020 Jun; 78(3):314-318. PubMed ID: 32540817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians.
    Ni Q; Chen X; Zhang P; Yang L; Lu Y; Xiao F; Wu B; Wang H; Zhou W; Dong X
    Orphanet J Rare Dis; 2022 Mar; 17(1):129. PubMed ID: 35313924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA sequencing analysis of cystic fibrosis transmembrane conductance regulator gene identifies cystic fibrosis-associated variants in the Severe Asthma Research Program.
    Izquierdo ME; Marion CR; Moore WC; Raraigh KS; Taylor-Cousar JL; Cutting GR; Ampleford E; Hawkins GA; Zein J; Castro M; Denlinger LC; Erzurum SC; Fahy JV; Israel E; Jarjour NN; Mauger D; Levy BD; Wenzel SE; Woodruff P; Bleecker ER; Meyers DA; Ortega VE
    Pediatr Pulmonol; 2022 Jul; 57(7):1782-1788. PubMed ID: 35451201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of Clinical Presentation in Patients Heterozygous for the F508del Cystic Fibrosis Variant: A Series of Three Cases and a Review of the Literature.
    Raymond CM; Gaul SP; Han S; Huang G; Dong J
    Cureus; 2023 Jun; 15(6):e40185. PubMed ID: 37431359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant.
    Kondratyeva E; Bukharova T; Efremova A; Melyanovskaya Y; Bulatenko N; Davydenko K; Filatova A; Skoblov M; Krasovsky S; Petrova N; Polyakov A; Adyan T; Amelina E; Shadrina V; Zhekaite E; Zodbinova A; Chernyak A; Zinchenko R; Kutsev S; Goldshtein D
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34071719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment.
    Raraigh KS; Aksit MA; Hetrick K; Pace RG; Ling H; O'Neal W; Blue E; Zhou YH; Bamshad MJ; Blackman SM; Gibson RL; Knowles MR; Cutting GR
    J Cyst Fibros; 2022 May; 21(3):463-470. PubMed ID: 34782259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.
    Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E
    J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoclastogenesis and sphingosine-1-phosphate secretion from human osteoclast precursor monocytes are modulated by the cystic fibrosis transmembrane conductance regulator.
    Jourdain ML; Sergheraert J; Braux J; Guillaume C; Gangloff SC; Hubert D; Velard F; Jacquot J
    Biochim Biophys Acta Mol Basis Dis; 2021 Mar; 1867(3):166010. PubMed ID: 33188942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the population structure of North American patients with cystic fibrosis.
    Li W; Sun L; Corey M; Zou F; Lee S; Cojocaru AL; Taylor C; Blackman SM; Stephenson A; Sandford AJ; Dorfman R; Drumm ML; Cutting GR; Knowles MR; Durie P; Wright FA; Strug LJ
    Clin Genet; 2011 Feb; 79(2):136-46. PubMed ID: 20681990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype.
    Tosco A; Castaldo A; Colombo C; Claut L; Carnovale V; Iacotucci P; Lucarelli M; Cimino G; Fabrizzi B; Caporelli N; Majo F; Ciciriello F; Padoan R; Poli P; Taccetti G; Centrone C; Casciaro R; Castellani C; Salvatore D; Colangelo C; Bonomi P; Castaldo G; Terlizzi V
    J Cyst Fibros; 2022 Sep; 21(5):850-855. PubMed ID: 35523714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.